View Older Stories View More Recent Stories

Sep 20, 2021 05:00PM Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:39AM Seagen (SGEN) and Genmab (GMAB) Present Encouraging Results From Two Cohorts of Phase 1b/2 innovaTV 205 Trial
Sep 19, 2021 11:30AM Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Sep 19, 2021 11:30AM Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Sep 9, 2021 08:00AM Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Sep 8, 2021 08:00AM Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
Aug 9, 2021 06:00AM Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Jul 29, 2021 04:02PM Seagen Reports Second Quarter 2021 Financial Results
Jul 9, 2021 02:12PM Astellas, Seagen (SGEN) Announce U.S. FDA Grants Regular Approval and Expands Indication for PADCEV for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 9, 2021 02:10PM U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 9, 2021 02:10PM U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 8, 2021 08:00AM Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
Jun 7, 2021 06:31AM SpringWorks Therapeutics (SWTX) Announces Clinical Collaboration with Seagen (SGEN) to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with R/R Multiple Myeloma
Jun 3, 2021 06:11AM Seagen (SGEN) Announces Long-Term Results from TUKYSA Pivotal Trial in Patients with HER2-Positive Breast Cancer During ASCO
Jun 3, 2021 06:00AM Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
Jun 2, 2021 08:00AM Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 19, 2021 05:21PM Seagen (SGEN) and Astellas Pharma Inc. Report Updated Results from Two Trials of PADCEV (enfortumab vedotin-ejfv)
May 19, 2021 05:04PM Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemothe
May 19, 2021 05:00PM Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemothe
Apr 29, 2021 04:02PM Seagen Reports First Quarter 2021 Financial Results
Apr 29, 2021 08:00AM Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
Apr 19, 2021 08:04AM Astellas and Seagen (SGEN) Announce U.S. FDA Acceptance of Two SBLAs for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Apr 19, 2021 08:00AM Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Apr 19, 2021 08:00AM Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Apr 9, 2021 04:00PM Genmab A/S (GMAB) and Seagen (SGEN) Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin BLA for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM  Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 08:00AM Seagen to Highlight Data from Novel Targeted Therapies at AACR
Apr 7, 2021 08:00AM Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021
Mar 5, 2021 08:00AM Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation
Feb 24, 2021 08:00AM Seagen to Present at the Cowen 41st Annual Healthcare Conference
Feb 18, 2021 08:03AM Astellas and Seagen (SGEN) Announce Submission of Two sBLA to U.S. FDA for PADCEV in Locally Advanced or Metastatic Urothelial Cancer
Feb 18, 2021 08:00AM Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 18, 2021 08:00AM Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Feb 12, 2021 02:16PM Astellas and Seagen (SGEN) Announce Presentation of Results from PADCEV Pivotal Trial in Patients with Previously Treated Advanced UC Who Were Ineligible for Cisplatin Chemotherapy
Feb 12, 2021 02:15PM Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Feb 12, 2021 02:15PM Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Feb 12, 2021 02:15PM Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Feb 12, 2021 02:15PM Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cispla
Feb 12, 2021 06:48AM Seagen (SGEN) Reports European Commission Approval of TUKYSA (tucatinib) for Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Feb 12, 2021 06:45AM European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Feb 11, 2021 04:02PM Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 10, 2021 04:47PM Seagen (SGEN), Genmab (GMAB) Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Jan 7, 2021 08:00AM Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
Dec 16, 2020 08:00AM Seagen to Present at the J.P. Morgan Healthcare Conference
Dec 11, 2020 08:00AM Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
Dec 11, 2020 07:23AM Seagen (SGEN) Announces Positive CHMP Opinion for TUKYSA for Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Dec 11, 2020 07:23AM Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
View More Recent Stories View Older Stories